Effect of Mifepristone on Serum VEGF and HGF in Patients with Endometriosis

OBJECTIVE To study mifepristone on serum vascular endothelial growth factor(VEGF) and hepatocyte growth factor(HGF) in patients with endometriosis. METHODS All of 116 cases of endometriosis after surgery were randomly divided into 2 groups, the observation group and the control group with 58 patients. The patients in the observation group were treated through mifepristone and the patients in the observation group were treated with gestrinone. Both groups were treated for 6 months. Serum VEGF and HGF were determined. RESULTS The total effective rates were 93.1% in the observation group and 82.8% in the control group, the two groups were significantly different(P0.05). After treatment, serum VEGF and HGF in observation group were significantly reduced compared with the control group(P0.05). CONCLUSION Mifepristone can be more significantly inhibit serum VEGF and HGF expression in patients with endometriosis.